7 years of historical data (2018–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Unicycive Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $144M | $53M | $21M | $8M | $24M | — | — | — |
| Enterprise Value | $119M | $28M | $12M | $8M | $8M | — | — | — |
| P/E Ratio → | -1.24 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 31.56 | 8.55 | — | — | — | — |
| P/B Ratio | 6.25 | 7.16 | — | — | 1.46 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 18.39 | 8.28 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -1898.2% to -3077.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -2028.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | — | — | -3077.6% | -1898.2% | — | — | — | — |
| Net Profit Margin | — | — | -4525.0% | -1898.8% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2028.1% | -2028.1% | — | -225.5% | -145.0% | — | — | — |
| ROA | -160.2% | -160.2% | -359.2% | -167.5% | -105.7% | -2249.3% | -9600.0% | -3862.1% |
| ROIC | — | — | — | — | -16223.5% | — | — | — |
| ROCE | -1527.6% | -1527.6% | — | -223.2% | -128.5% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $26M exceeds total debt of $773000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | — | — | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3.41 | — | — | -0.99 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -452.35 | -452.35 | -253.34 | -3008.67 | -14.29 | -8.28 | -14.12 | — |
Net cash position: cash ($26M) exceeds total debt ($773000)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.28x means Unicycive Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.81x to 1.28x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Quick Ratio | 1.28 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Cash Ratio | 1.08 | 1.08 | 0.55 | 0.14 | 7.88 | — | 0.02 | 0.02 |
| Asset Turnover | — | — | 0.05 | 0.34 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Unicycive Therapeutics, Inc. returns 2.4% to shareholders annually primarily through dividends.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.4% | 2.1% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 2.4% | 2.1% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $2M | $2M | $1M | $2M | $847146 | $794322 |
Compare UNCY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| UNCYYou | $144M | -1.2 | — | — | — | — | -2028.1% | — | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how UNCY stacks up against sector leader United Therapeutics Corporation.
Start ComparisonUnicycive Therapeutics, Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Unicycive Therapeutics, Inc.'s return on equity (ROE) is -2028.1%. The historical average is -185.3%.
Based on historical data, Unicycive Therapeutics, Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Unicycive Therapeutics, Inc.'s current dividend yield is 2.36%.